Dr Bradley McGregor speaks to ecancer about the CLEAR study which explores lenvatinib plus pembrolizumab compared to sunitinib in patients with advanced renal cell carcinoma.
This phase III trial showed statistically significant progression free survival and overall survival benefits, and improved overall response rate with the lenvatinib pembrolizumab combo in the first line setting.
Lenvatinib plus pembrolizumab continued to show a clinically meaningful benefit vs sunitinib, consistent with prior results. A large proportion of patients in the experimental arm completed 2 years of pembrolizumab and continued with lenvatinib monotherapy with ongoing clinical benefit.
These updated results further support lenvatinib plus pembrolizumab as a standard of care in first line aRCC.
